Literature DB >> 15448685

4-1BB-mediated immunotherapy of rheumatoid arthritis.

Su K Seo1, Jae H Choi, Young H Kim, Woo J Kang, Hye Y Park, Jae H Suh, Beom K Choi, Dass S Vinay, Byoung S Kwon.   

Abstract

Collagen type II-induced arthritis is a CD4(+) T-cell-dependent chronic inflammation in susceptible DBA/1 mice and represents an animal model of human rheumatoid arthritis. We found that development of this condition, and even established disease, are inhibited by an agonistic anti-4-1BB monoclonal antibody. Anti-4-1BB suppressed serum antibodies to collagen type II and CD4(+) T-cell recall responses to collagen type II. Crosslinking of 4-1BB evoked an antigen-specific, active suppression mechanism that differed from the results of blocking the interaction between 4-1BB and its ligand, 4-1BBL. Anti-4-1BB monoclonal antibodies induced massive, antigen-dependent clonal expansion of CD11c(+)CD8(+) T cells and accumulation of indoleamine 2,3-dioxygenase in CD11b(+) monocytes and CD11c(+) dendritic cells. Both anti-interferon-gamma and 1-methyltryptophan, a pharmacological inhibitor of indoleamine 2,3-dioxygenase, reversed the anti-4-1BB effect. We conclude that the suppression of collagen-induced arthritis was caused by an expansion of new CD11c(+)CD8(+) T cells, and that interferon-gamma produced by these cells suppresses antigen-specific CD4(+) T cells through an indoleamine 2,3-dioxygenase-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15448685     DOI: 10.1038/nm1107

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  125 in total

1.  Reverse signaling through the costimulatory ligand CD137L in epithelial cells is essential for natural killer cell-mediated acute tissue inflammation.

Authors:  Hye J Kim; Jong S Lee; Jung D Kim; Hee J Cha; Ahra Kim; Sun K Lee; Sang C Lee; Byoung S Kwon; Robert S Mittler; Hong R Cho; Byungsuk Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 2.  Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.

Authors:  G C Prendergast; M Y Chang; L Mandik-Nayak; R Metz; A J Muller
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

3.  Role of IFN-γ in the establishment of anterior chamber-associated immune deviation (ACAID)-induced CD8+ T regulatory cells.

Authors:  Kathryn Paunicka; Peter W Chen; Jerry Y Niederkorn
Journal:  J Leukoc Biol       Date:  2011-12-16       Impact factor: 4.962

Review 4.  Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets.

Authors:  Alison M Gizinski; David A Fox; Sujata Sarkar
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-08       Impact factor: 4.098

Review 5.  Mechanisms of self-nonself discrimination and possible clinical relevance.

Authors:  Carolin Daniel; Jens Nolting; Harald von Boehmer
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

6.  CD137-CRDI is not necessary in the role of contacting its natural ligand.

Authors:  Ling Yi; Zhuohong Yan; Hongyan Jia; Xiaojue Wang; Yanlin Zhao; Hongtao Zhang
Journal:  Immunol Cell Biol       Date:  2016-08-16       Impact factor: 5.126

7.  CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype.

Authors:  Yuwen Zhu; Gefeng Zhu; Liqun Luo; Andrew S Flies; Lieping Chen
Journal:  Blood       Date:  2007-01-23       Impact factor: 22.113

Review 8.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

Review 9.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 10.  Inhibitory CD8+ T cells in autoimmune disease.

Authors:  Masakatsu Suzuki; Christine Konya; Jörg J Goronzy; Cornelia M Weyand
Journal:  Hum Immunol       Date:  2008-09-21       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.